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Abstract
We report the cognitive features and progression of Parkinson’s disease (PD) in five patients with concurrent Gaucher dis-
ease. The patients presented at an earlier age than patients with sporadic PD, as previously noted by others; but in contrast to 
many previous reports, our patients followed a variable clinical course. While two patients developed early cognitive deficits 
and dementia, three others remained cognitively intact over the follow-up period. Thus, in this small case series, PD in the 
context of GD more closely resembles idiopathic PD in terms of its clinical heterogeneity in contrast to PD associated with 
GBA heterozygote mutations.
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Introduction
Heterozygous mutations in the acid glucocerebrosidase gene 
(GBA1) are the most important genetic risk factor associated 
with so called “sporadic” Parkinson’s Disease (PD) [1–9]. 
However, the link between mutations in glucocerebrosi-
dase and PD was not discovered through genetic studies 
but through astute clinical observations of the association 
of PD in patients with Gaucher Disease (GD) patients [1, 
10–13]. Furthermore, large-scale genetic studies failed con-
sistently to identify the associated GBA mutations because 
of the apparent absence of a gene-dose effect or because of 
the association in Parkinson disease with multiple distinct 
mutant GBA1 alleles; these alleles, moreover, have divergent 
distributions in different human populations [8].
PD, a progressive neurodegenerative disorder, typically 
presenting in patients over 65 years of age, in whom it pre-
sents with a triad of motor impairments including bradyki-
nesia, rigidity and tremor - as well as non-motor features [1, 
12, 14, 15]. GD, multisystem glycosphingolipid disorder, 
is one of the most frequent Lysosomal Storage Disorders 
(LSDs) and is caused by biallelic defects in the GBA1 gene 
[13, 16]. In patients with both GD and PD, the manifesta-
tions of Gaucher disease are usually reported to be mild [12, 
17] and the risk factors for developing PD in such patients 
are similar to those for idiopathic PD, namely male gender 
and older age [2, 15]. In these patients, GD usually predates 
the onset of PD, although rare reports of patients developing 
PD before their GD have been described [1, 3, 10, 18, 19]. In 
the less frequently reported patients with concurrent PD/GD 
hitherto described, the motor features have been reported as 
typical of those in idiopathic PD, including an asymmetric 
onset of bradykinesia, rigidity, and resting tremor [1, 12, 14, 
20] and where pathological data is available, Lewy bodies 
have been found within the brainstem, cortex and hippocam-
pus [13, 17, 21, 22]. Detailed neuropsychological and longi-
tudinal characterization of PD/GD cases has not previously 
been reported. Here, we describe a series of five patients 
with concurrent PD and GD in whom detailed clinical and 
neuropsychological data were collected prospectively for up 
to 2 years.
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Methods
Patients with GD and either concurrent PD or Parkinsonism 
were identified from medical case note review of patients 
attending the LSD clinic at Addenbrooke’s hospital, Cam-
bridge. Informed, written consent was taken from all par-
ticipants following ethical approval of the study (REC 13/
EE/0171). This study has been performed in accordance with 
the ethical standards established in the 1964 Declaration of 
Helsinki and its later amendments. The diagnosis of PD was 
confirmed using UK PD Brain Bank criteria [1, 12, 14, 15, 
23]. Patients were assessed annually for up to 2 years. At 
each visit a detailed medical history was taken and neurolog-
ical evaluation performed to assess features of Parkinsonism, 
and Hoehn and Yahr stage (H&Y). Cognitive function was 
assessed using the Addenbrooke’s Cognitive Examination - 
Revised (ACE-R), [2, 18] Mini-Mental State Examination 
(MMSE), [19, 24] verbal fluency tests (including phonemic 
fluency for letters F,A,S and semantic fluency), the penta-
gon copying test [25] and the Frontal Assessment Battery 
(FAB) [12, 20, 26]. The Beck Depression Inventory (BDI) 
was used to assess depression [21, 27, 28] and the Behav-
ioural questionnaire apathy evaluation scale (AES), was 
used to rate apathy [22]. Daytime sleepiness was assessed 
using the Epworth Sleepiness Scale (ESS). The EuroQol five 
dimensions health questionnaire (EQ-5D) was used to assess 
overall health. One patient who lived abroad was unable to 
attend the clinic and so was assessed via Skype using similar 
cognitive and motor tools, but rigidity assessments and pos-
tural stability were omitted and the behavioral component of 
the FAB could not be completed (Table 1).
Case 1
Case 1 was diagnosed with GD aged 27 years and had a 
past medical history of splenectomy, cholecystectomy, oste-
oarthritis of the knees, tendinosis of the right shoulder and 
thrombocytopaenia. She was compound heterozygous for 
N370S/L444P. She was a right-handed non-smoker with no 
family history of PD. Medications included 400 IU imiglu-
cerase weekly and prophylactic penicillin. At her baseline 
visit (age 50) her walking was slow and she scored highly 
for apathy but had no tremor or rigidity, so did not meet 
UKPDS Brain Bank diagnostic criteria for PD. She had no 
significant cognitive deficits. When seen 1 year later, she 
had developed more overt bradykinetic hand movements on 
the right, and right upper limb rigidity as well as a shuffling 
gait. No significant cognitive deficits were present but her 
apathetic symptoms persisted. A diagnosis of PD was made 
at this time. At the 2 year follow-up after baseline assess-
ment, 1 year after being diagnosed with PD, her motor state 
had deteriorated with increasing right-sided bradykinesia, 
rigidity and tremor and worsening gait impairment but no 
postural instability. Overall her symptoms remained mild 
with no cognitive deterioration and she did not require any 
PD medication.
Case 2
Case 2 was assessed via Skype. GD was detected 33 years 
before entry to study when she presented following a road 
traffic accident when an enlarged spleen was detected along 
Table 1  Demographics of the GD/PD patients
Five patients with both PD and GD were recruited. All patients had genetically confirmed GD. All were of non-Jewish descent and from the UK 
or Ireland
a At entry into the study
b Age at leaving full time education (Edu)
c In first degree relative
ID Gender GBA mutation Agea Edub PD 
disease 
 durationa
GD 
disease 
 durationa
Family history of  PDc Presenting PD fea-
tures
Presenting GD features
Case 1 Female N370S/L444P 50 27 − 1 23 No Bradykinesia and 
rigidity
Splenomegaly
Case 2 Female N370S/L444P 60 21 1 33 No Tremor, bradykinesia 
and rigidity
Splenomegaly
Case 3 Female N370S/L444P 72 15 5 22 Yes Olfactory loss and 
tremor
Osteoporosis, throm-
bocytopenia
Case 4 Male L444P/R463C 56 16 8 14 No Tremor, bradykinesia 
and rigidity
Splenomegaly, oste-
onecrosis
Case 5 Female R463C/R463C 58 16 10 20 Unknown Tremor, bradykinesia 
and REM sleep 
disturbance
Splenomegaly, osteo-
porosis
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with unaccountable bruising on her legs. The current spe-
cific GD treatment was imiglucerase. She was a right-handed 
non-smoker with a compound heterozygous mutation 
N370S/L444P. The participant had no family history of PD 
but had a sibling with GD now aged 68 years, who is unaf-
fected by Parkinson disease. She was diagnosed with PD at 
the age of 59. On her initial assessment at the age of 60, she 
had moderate bradykinesia and mild tremor in the left upper 
limb. Cognition was intact, although mild depression and 
excessive daytime sleepiness were noted. At her first follow-
up assessment at 1 year, her motor symptoms had progressed 
but remained unilateral with left upper limb bradykinesia, 
rigidity and rest tremor. Her cognitive function remained 
intact and she was not receiving any anti-PD medication.
Case 3
Case 3 was diagnosed with GD at the age of 50 years when 
she presented with mild osteoporosis and thrombocytopenia 
and was found to be compound heterozygous for N370S/
L444P. She was a right-handed non-smoker. She had two 
siblings, one brother had been diagnosed with both PD and 
GD and a second brother had a diagnosis of GD. She was 
diagnosed with PD at the age of 67. Her presenting features 
of PD included loss of smell, depression, tremor, slowness 
and stiffness in the right hand/arm. Her medications included 
imiglucerase therapy, bisoprolol, lansoprazole, citalopram, 
Co-benelodopa, ropinirole, domperidone and rivastigmine. 
On her first assessment at the age of 72 years, she reported 
pain, stiffness and mild tremor in the right arm, and there 
was objective evidence of unilateral bradykinesia, rigidity 
and tremor. She also had the evidence of significant cogni-
tive impairment with an ACE-R 78/100 and an inability to 
copy the intersecting pentagons figure. She met Movement 
Disorder Society criteria for a diagnosis of PD dementia. 
She was noted to be apathetic (scoring highly on the AES). 
She was followed up and 1 year later she had developed 
bilateral motor features but without postural instability, her 
cognitive function remained stable (ACE-R 80/100) and she 
had developed mild depression.
Case 4
Case 4 was diagnosed with GD at the age of 42 after present-
ing with osteonecrosis, and was found to carry compound 
heterozygous mutations, L444P and R463C. He was a left-
handed ex-smoker, with no family history of PD. PD was 
diagnosed at the age of 48 when he presented with a mild 
right upper limb tremor, mild bilateral rigidity, bradykin-
esia, poor postural reflexes, poor balance and hypophonia. 
Medications included imiglucerase therapy, pramipexole, 
Co-careldopa, amantadine and Co-beneldopa. At his first 
assessment at the age of 56 years, motor examination 
revealed a Parkinsonian gait and postural instability. Neu-
ropsychological testing revealed visuospatial dysfunction 
with impaired pentagon copying. He had a moderate depres-
sion score of 24 on the BDI. 1 year later he had developed 
more axial features, including speech disturbance and pos-
tural instability. Neuropsychological testing again showed 
predominantly visuospatial dysfunction but with a normal 
ACE-R score of 94 and moderate depression.
Case 5
Case 5 was diagnosed with GD at the age of 38 when she had 
a splenectomy, and was noted to have osteoporosis. PD was 
diagnosed at the age of 48 when she presented with a REM 
sleep disturbance, tremor and bradykinesia. She was treated 
with imiglucerase therapy and PD medication that included 
Madopar, entacapone and rivastigmine for cognitive impair-
ment. Other medications included ibuprofen, paracetamol, 
simvastatin, alfacalcidol and senna, 9-alpha fludrocortisone, 
mirtazapine and penicillin V. She was first assessed at the 
age of 58 years, and by this stage she had developed motor 
fluctuations and dyskinesias. She was unable to complete 
formal cognitive testing but she had symptomatic cognitive 
dysfunction and visual hallucinations. She died within a year 
of her first assessment so no longer term follow-up data was 
available (Table 2).
Discussion
In this study, a series of five cases of PD associated with 
Type I GD are reported. The occurrence of PD in GD 
patients has not been associated with any particular GBA 
mutation [2]: all patients in this series, harboured one copy 
of the GBA1 L444P mutation in trans with either N370S or 
R463C. Presenting features were similar in all cases, with 
all having the typical motor features seen in sporadic PD. 
Tremor was seen in most cases and consistent with other 
studies of such patients [1, 12, 14, 23]. The average age of 
PD onset was 53.8 years in our cases, and three presented 
before the age of 50 years. In comparison, the average age 
of onset of idiopathic PD is about 70 years [24]. From the 
first publication of six patients in 1996, other authors have 
similarly noted an earlier age of onset of PD in patients with 
established GD [12, 26].
In our small case series, we found that cognitive func-
tion was well preserved in three of the five patients. We 
acknowledge that two of these cases were assessed in the 
early stages of PD with relatively short follow-up durations, 
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but it is noteworthy that case 4 had global cognitive scores 
(ACE-R) within the normal range even at 8–9 years into 
the course of their PD. This is compatible with growing 
evidence suggesting that cognition in GD patients with PD 
can be preserved or only mildly impaired even in the late 
stages of the disease, [27, 28]; it, moreover, suggests that GD 
mutations are not a reliable predictor of rapid progression 
to dementia in PD.
Our findings should be considered in the context of 
several large-scale studies that describe more rapid cog-
nitive decline in patients with PD who are heterozygotes 
for mutations in GBA1 [29–31]. This cognitive decline has 
tentatively been linked to diminished lysosomal acid glu-
cosidase activity, but if this were the causal explanation, 
then one would expect patients with PD in the context of 
established GD to show consistent early decline of their cog-
nitive powers. However, this is not necessarily the case—at 
least as shown in this small case series. It is remotely pos-
sible that the enzyme replacement therapy (ERT) taken by 
our GD patients may affect progression of PD as all of the 
patients in our cohort were receiving long-term ERT. How-
ever, this ERT, a macrophage-targeted large glycoprotein 
(MW ≈ 68 kDa) is considered not to cross the blood–brain 
barrier [32]. Alternatively, ERT may have systemic effects; 
which in turn indirectly affects the central pathology of PD. 
This is a putative mechanism that we have suggested may 
apply to the peripheral immune changes that are associated 
with PD [33].
For Gaucher’s patients receiving ERT, the therapy is not 
predicted to cross the blood brain barrier (BBB). However, 
there is evidence to suggest that the BBB is dysfunctional 
in Parkinson’s disease [34], which may mean that it is 
partially permeable to circulating molecules including pro-
teins. If this were the case in patients with PD and GD the 
ERT might protect vulnerable dopaminergic neurons from 
cytotoxic injury. Alternatively systemic ERT could influ-
ence the peripheral immune system (known to be disturbed 
in GD), and dampen the activated immunity with cytotoxic 
effects that have been documented in PD [33].
In conclusion, in this case series of adults with the rare 
combination of GD and PD, assessed using a range of 
motor and non-motor assessments over a 12–24 month 
period of follow-up, rapid disease progression and early 
cognitive impairment were not consistently found. We thus 
contend that these are not universal features of this condi-
tion during its early phases of evolution; as such patients 
are clinically and cognitively heterogeneous. This con-
trasts with the often-stated stereotypic clinical picture 
of rapid progression and early dementia in patients with 
PD who are heterozygous for GBA1 mutations; it, moreo-
ver, suggests that the link between PD, Parkinson’s Dis-
ease Dementia (PDD) and its associated alpha-synuclein 
pathology is not simply related to the residual activity of 
lysosomal glucocerebrosidase.
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Table 2  Baseline and follow-up 
clinical data for PD/GD patients
ACE-R Addenbrooke’s cognitive examination revised, MMSE mini mental state examination, AES apathy 
evaluation scale, BDI beck depression inventory, H&Y Hoehn and Yahr scale, SF semantic fluency, VF FAS 
verbal fluency for letters F, A, S, FAB frontal assessment battery. Visits were 12 months apart
Case 1 Case 2 Case 3 Case 4
Visit 1 Visit 2 Visit 3 Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2
ACE-R total 100 99 100 92 95 78 80 94 93
MMSE total 30 29 30 29 30 21 26 28 29
Attention 18 18 18 18 18 11 16 17 18
Memory 26 26 26 24 24 23 24 25 24
Fluency 14 14 14 10 11 7 6 11 13
Language 26 25 26 24 26 24 25 26 25
Visuospatial 16 16 16 16 16 14 7 15 13
Pentagon 2 2 2 2 2 1 0 1 1
Phonemic fluency 19 18 21 8 16 6 7 16 22
SF 60 s 23 22 20 18 16 13 9 16 17
SF 90 s 29 32 30 23 19 15 9 21 22
VF FAS 51 50 50 26 45 49
AES 21 29 27 57
BDI 1 0 9 23 24
FAB 18 18 18 18
H&Y 0 1 1 1 1 1 2 3 3
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